
    
      OVERVIEW OF TRIAL DESIGN:

      This trial is a a two-arm, multicenter, open labelled, prospective, randomized phase III
      studies. Eligible patients with locally advanced (T4 or T3 with extramural depthâ‰§5 mm) colon
      cancer patients will be randomly assigned, in a 1:1 ratio, to receive either perioperative or
      postoperative chemotherapy.
    
  